Trials / Terminated
TerminatedNCT04300114
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Fluzoparib Monotherapy in Patients With gBRCA/PALB2 Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the tolerability, safety and efficacy of maintenance Fluzoparib monotherapy in patients with gBRCA/PALB2 mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib | Fluzoparib capsules po. 150 mg twice daily |
| DRUG | Placebo | Placebo capsules po. twice daily |
Timeline
- Start date
- 2020-08-19
- Primary completion
- 2022-02-18
- Completion
- 2022-02-18
- First posted
- 2020-03-09
- Last updated
- 2024-03-28
Locations
23 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04300114. Inclusion in this directory is not an endorsement.